Fig. 4
From: WEE1 and PARP-1 play critical roles in myelodysplastic syndrome and acute myeloid leukemia treatment
MK-1775 combined with talazoparib induced cytotoxicity in the MDS cells. SKM-1 cells were treated with MK-1775 and/or talazoparib for 72 h. Cellular proliferation was evaluated with a cell counting kit-8. (A) MDS cells were incubated with MK-1775 or talazoparib for 72 h. The intracellular ATP levels were determined using a Cell ATP assay reagent Ver.2 kit. (B) SKM-1 cells were treated with MK-1775 and/or talazoparib for 24 h. The total extracts were examined by immunoblot analysis with antibodies against γ-H2AX, cleaved caspase 3, and β-actin. (C) Cell cycle phase profiling was determined by a BD Cycletest™ Plus DNA Reagent Kit using SKM-1 cells treated with MK-1775 and/or talazoparib for 24 h. A representative histogram for each condition is illustrated. (D) SKM-1 cells were cultured in RPMI medium with MK-1775 and/or talazoparib for 24 h. ROS activity was analyzed using a ROS Assay Kit -Highly Sensitive DCFH-DA, according to the manufacturer’s protocol. Significance was expressed as *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, and ns, not significant